Abstract:Dysfunctional mitochondrial metabolism and sustained de novo lipogenesis are characteristic of non-alcoholic fatty liver disease (NAFLD), a common comorbidity of obesity and type 2 diabetes. We hypothesize that sustained de novo lipogenesis, through its biochemical relationships with mitochondria (e.g., tri-carboxylic acid (TCA) cycle) can contribute to dysfunctional oxidative flux during NAFLD. In study 1, male mice (C57BL/6JN) were fed either a low-fat (LF; 10% fat Kcal), high-fat (HF; 60% fat Kcal), or high-fructose/HF diet (HFr/HF; 34.9% fructose Kcal, 25% fat Kcal) for 24-wks. Liver mitochondria were utilized to determine oxygen consumption and were incubated in a buffer (for 5-min) to determine changes in TCA cycle intermediates, using gas chromatography-mass spectrometry (GC-MS). Plasma and liver samples were utilized for GC-MS based metabolomics and determination of gene and protein expression. In study 2, C57BL/6JN mice were provided 30% fructose in drinking water (FW) for 2-wks to induce hepatic de novo lipogenesis vs. mice given regular water (RW). Liver mitochondria were incubated in a buffer containing 1mM [ 13 C 3 ]pyruvate or 2.5mM [ 13 C 4 ]malate for 5-min. Isotopomer distribution of the TCA cycle intermediates were determined using GC-MS. Both HF and HFr/HF diets resulted in similar degrees of hepatic steatosis. However, lipogenic gene expression ( Scd1, Acyl, Fasn) and fasting plasma β-hydroxybutyrate levels were higher (p<0.001) in HFr/HF vs. HF group. Further, the feeding-to-fasting induction of genes involved in lipid oxidation ( Cpt1α, Lcad, Hmgcs2) was higher (p ≤0.01) in HFr/HF vs. HF livers. After 5-min of incubation, the HFr/HF liver mitochondria had higher (p<0.05) TCA cycle intermediates vs. the HF. The HFr/HF mitochondria also had higher expression of oxidative phosphorylation proteins and higher oxygen consumption rates (OCR), vs. the HF (p<0.05). In study 2, fructose in drinking water induced hepatic de novo lipogenesis. Induction of lipogenesis was also accompanied by higher mitochondrial OCR, higher reactive oxygen species, and higher TCA cycle metabolism (p<0.05). Gene expression of components of the mitochondrial nutrient shuttles ( SLC25A13, MPC1, MPC2, ME1) was upregulated in lipogenic livers (p<0.05). Incorporation of 13 C from [ 13 C 4 ]malate into pyruvate and α-ketoglutarate, indices of malic enzyme and TCA cycle activity, were higher (p<0.05) in lipogenic livers. Similarly, incorporation of 13 C from [ 13 C 3 ]pyruvate into aspartate and citrate, indices of pyruvate carboxylase and pyruvate dehydrogenase activity, were also higher (p<0.05) in lipogenic livers. These results demonstrate that the induction of several facets of mitochondrial oxidative metabolism and de novo lipogenesis accompany a carbohydrate-rich dietary milieu and NAFLD. Sustained induction of both de novo lipogenesis and mitochondrial oxidative function could contribute to the progression of metabolic dysfunction during NAFLD. National Institutes of Health R01 DK112865 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction

Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective.

Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease

Is Nrf2-ARE a Potential Target in NAFLD Mitigation?

Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2

O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease

Sulforaphane Ameliorates Non-Alcoholic Steatohepatitis by KLF4-mediated Macrophage M2 Polarization

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats

Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)

Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy

Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches

CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)

Impact of sustained de novo lipogenesis on mitochondrial dysfunction and hepatocellular redox during fatty liver disease

Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease